alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 71 studies by Schneider JA (page 1 of 3) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Molecular psychiatry 2016-03-29

The lack of strong association between brain beta-amyloid deposition and cognitive impairment has been a challenge for the Alzheimer's disease (AD) field. 4 key findings →

Design: meta-analysis Participants: 678 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Participation in cognitively stimulating activities and risk of incident Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 70 out of 100. JAMA 2002-02-01

These results suggest that frequent participation in cognitively stimulating activities is associated with reduced risk of AD. 5 key findings →

Design: cohort study Participants: 111 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Neurology 2015-11-04

We tested the hypothesis that cerebral amyloid angiopathy (CAA) is related to Alzheimer disease (AD) dementia and decline in multiple cognitive systems in old age, independent of AD plaque and tangle pathology and other common age-related neuropathologies. 4 key findings →

Design: longitudinal study Participants: 1,113 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 69 out of 100. The Lancet. Neurology 2016-06-14

Each level increase in the severity of atherosclerosis or arteriolosclerosis was associated with significantly higher odds of Alzheimer's disease dementia (odds ratio [OR] for atherosclerosis 1·33, 95% CI 1·11-1·58; OR for arteriolosclerosis 1·20, 1·04-1·40). 4 key findings →

Design: cohort study Participants: 1,143 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cerebral amyloid angiopathy pathology and cognitive domains in older persons

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Annals of neurology 2010-11-08

Subjects were 404 persons in the Religious Orders Study, a cohort study of aging, who underwent annual clinical evaluations, including 19 neuropsychological tests from which 5 cognitive domain and global summary scores were derived, and brain autopsy at time-of-death (mean age-at-death 86). 4 key findings →

Design: cohort study Participants: 404 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Assessing Cognitive Decline and Dementia Risk in Black and White Older Adults With Blood Biomarkers pTau217, GFAP, NfL, and Aβ Ratio

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Neurology 2025-10-28

Biomarkers were measured in 431 Black and 583 White participants (mean age of 77 and 80 years and 17% and 21% of men, respectively), generating a balanced sample of 366:366. 3 key findings →

Design: cohort Participants: 1,014 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Impact of multiple pathologies on the threshold for clinically overt dementia

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Acta neuropathologica 2017-05-09

Longitudinal clinical-pathological studies have increasingly recognized the importance of mixed pathologies (the coexistence of one or more neurodegenerative and cerebrovascular disease pathologies) as important factors in the development of Alzheimer's disease (AD) and other forms of dementia. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Much of late life cognitive decline is not due to common neurodegenerative pathologies

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Annals of neurology 2013-07-10

The pathologic indices of Alzheimer disease, cerebrovascular disease, and Lewy body disease accumulate in the brains of older persons with and without dementia, but the extent to which they account for late life cognitive decline remains unknown. 4 key findings →

Design: longitudinal study Participants: 856 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

CR1 is associated with amyloid plaque burden and age-related cognitive decline

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Annals of neurology 2011-03-09

We found that common variation at the CR1 locus has a broad impact on cognition and that this effect is largely mediated by an individual's amyloid plaque burden. 4 key findings →

Design: cohort study Participants: 1,666 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Association of Seafood Consumption, Brain Mercury Level, and APOE ε4 Status With Brain Neuropathology in Older Adults

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA 2016-02-01

Among the 286 autopsied brains of 544 participants, brain mercury levels were positively correlated with the number of seafood meals consumed per week (ρ = 0.16; P = .02). 5 key findings →

Design: cohort study Participants: 286 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep

✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA neurology 2013-12-01

Better sleep consolidation attenuates the effect of APOE genotype on incident AD and development of neurofibrillary tangle pathology. 2 key findings →

Design: cohort study Participants: 698 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. The Lancet. Neurology 2018-08-06

APOE ε4 count was associated with higher TDP-43 proteinopathy stage (odds ratio [OR] 2·0, 95% CI 1·6-2·6; p=1·9 × 10 -9 ) and TDP-43 burden (0·40, 0·28-0·52; p=1·2 × 10 -10 ). 3 key findings →

Design: cohort study Participants: 15 Evidence: moderate

Full summary, score breakdown and related studies → Original source

The time course of motor and cognitive decline in older adults and their associations with brain pathologies: a multicohort study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. The lancet. Healthy longevity 2024-04-03

The combinations of pathologies of Alzheimer's disease and related dementias associated with cognitive and motor decline and their onsets of associations varied; only tau tangles, Parkinson's disease pathology, and macroinfarcts were associated with decline of all three phenotypes. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source

TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Brain : a journal of neurology 2016-11-01

We tested the hypotheses that TDP-43 with Alzheimer's disease pathology is a common mixed pathology; is related to increased likelihood of expressing clinical Alzheimer's-type dementia; and that TDP-43 pathologic stage is an important determinant of clinical Alzheimer's-type dementia. 5 key findings →

Participants: 398 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed